
Switching Anti-CGRP Monoclonal Antibody Therapy in Nonresponders with Migraine May Reduce Monthly Headache Days
Switching between anti-CGRP monoclonal antibodies (mAbs) significantly reduced monthly headache days (MHDs) in patients with migraine who did not respond to initial treatment, according to a new retrospective study published in the journal Headache. Among …